ES2219577T3 - SYNTHESIS OF ACID R (+) ALPHA-LIPOIC. - Google Patents
SYNTHESIS OF ACID R (+) ALPHA-LIPOIC.Info
- Publication number
- ES2219577T3 ES2219577T3 ES01986686T ES01986686T ES2219577T3 ES 2219577 T3 ES2219577 T3 ES 2219577T3 ES 01986686 T ES01986686 T ES 01986686T ES 01986686 T ES01986686 T ES 01986686T ES 2219577 T3 ES2219577 T3 ES 2219577T3
- Authority
- ES
- Spain
- Prior art keywords
- acid
- dihalo
- octanoic
- racemic
- methylbenzylamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002253 acid Substances 0.000 title claims abstract description 83
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 16
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 15
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 title claims description 29
- 238000000034 method Methods 0.000 claims abstract description 54
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- 150000002148 esters Chemical class 0.000 claims abstract description 17
- 125000001424 substituent group Chemical group 0.000 claims abstract description 13
- 125000005907 alkyl ester group Chemical group 0.000 claims abstract description 12
- 239000003960 organic solvent Substances 0.000 claims abstract description 11
- 238000000926 separation method Methods 0.000 claims abstract description 11
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000007864 aqueous solution Substances 0.000 claims abstract description 9
- 239000003513 alkali Substances 0.000 claims abstract description 8
- 150000007513 acids Chemical class 0.000 claims abstract description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 7
- 239000011707 mineral Substances 0.000 claims abstract description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000010790 dilution Methods 0.000 claims abstract description 6
- 239000012895 dilution Substances 0.000 claims abstract description 6
- 238000005886 esterification reaction Methods 0.000 claims abstract description 6
- 238000000746 purification Methods 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 230000032050 esterification Effects 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 238000001953 recrystallisation Methods 0.000 claims abstract description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 3
- 125000005496 phosphonium group Chemical group 0.000 claims abstract description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 3
- 239000011574 phosphorus Substances 0.000 claims abstract description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 27
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 238000006555 catalytic reaction Methods 0.000 claims description 7
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 6
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 5
- SRRKNRDXURUMPP-UHFFFAOYSA-N sodium disulfide Chemical compound [Na+].[Na+].[S-][S-] SRRKNRDXURUMPP-UHFFFAOYSA-N 0.000 claims description 5
- HSKAEXWPLIDFGC-UHFFFAOYSA-N 6,8-dichlorooctanoic acid Chemical compound OC(=O)CCCCC(Cl)CCCl HSKAEXWPLIDFGC-UHFFFAOYSA-N 0.000 claims description 4
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 150000002019 disulfides Chemical class 0.000 claims description 3
- 150000004702 methyl esters Chemical class 0.000 claims description 3
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- LTJSXGVQCAVSJW-UHFFFAOYSA-N [K+].[K+].[S-][S-] Chemical compound [K+].[K+].[S-][S-] LTJSXGVQCAVSJW-UHFFFAOYSA-N 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 238000010931 ester hydrolysis Methods 0.000 claims description 2
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical class ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 2
- 150000004714 phosphonium salts Chemical class 0.000 claims 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims 2
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical class S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 claims 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 150000003997 cyclic ketones Chemical class 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical class 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- BJQWBACJIAKDTJ-UHFFFAOYSA-N tetrabutylphosphanium Chemical compound CCCC[P+](CCCC)(CCCC)CCCC BJQWBACJIAKDTJ-UHFFFAOYSA-N 0.000 claims 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 abstract description 14
- 230000007062 hydrolysis Effects 0.000 abstract description 3
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 3
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 abstract 1
- 238000003408 phase transfer catalysis Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 14
- 239000012071 phase Substances 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- -1 for example Chemical class 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000019136 lipoic acid Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229960002663 thioctic acid Drugs 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- VROFMCACQMRGHY-UHFFFAOYSA-N methyl 6,8-dichlorooctanoate Chemical compound COC(=O)CCCCC(Cl)CCCl VROFMCACQMRGHY-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 2
- UTUNURLNZXJIEN-UHFFFAOYSA-N 2,2-dichlorooctanoic acid Chemical compound CCCCCCC(Cl)(Cl)C(O)=O UTUNURLNZXJIEN-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- RKHXQBLJXBGEKF-UHFFFAOYSA-M tetrabutylphosphanium;bromide Chemical compound [Br-].CCCC[P+](CCCC)(CCCC)CCCC RKHXQBLJXBGEKF-UHFFFAOYSA-M 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- General Preparation And Processing Of Foods (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Biological Depolymerization Polymers (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
Abstract
Procedimiento de síntesis de ácido R(+)a-lipoico que comprende las siguientes etapas: a) salificación de ácido 6, 8-halo-octanoico racémico con S(-)~-metilbencilamina, tomando la relación molar S(-)~metilbencilamina/ácido 6, 8-dihalo-octanoico racémico un valor entre 0, 45 y 0, 65; b) separación por filtración de la sal diastereoisomérica cristalizada de S(-)-metilbencilamina-ácido R(+)-6, dihalo-octanoico; c) purificación por recristalización de la sal diastereoisomérica de S(-)-metilbencilamina-ácido R(+)-6, 8-dihaoctanoico d) separación de la sal diastereoisomérica para obtener ácido R(+)6, 8-dihalo-octanoico mediante la reacción de dicha sal con ácidos minerales fuertes diluidos en una solución acuosa, siendo la dilución de entre 2% y 10% en peso; e) esterificación del ácido R(+)6, 8-dihalo-octanoico para obtener el éster alquílico correspondiente; f) reacción del éster alquílico de ácido R(+)6, 8-dihalo-octanoico en un solvente orgánico con una solución acuosa de disulfuro alcalino enpresencia de un compuesto para la catálisis de transferencia de fase que se ha seleccionado del grupo formado por sales cuaternarias de fosfonio o amonio cuya fórmula general es: **(fórmula)** donde: A es nitrógeno o fósforo, X se selecciona del grupo formado por CI, Br, I, HSO4 y H2PO4, y los sustituyentes R1, R2, R3 y R4 se seleccionan del grupo formado por radicales de alquilo lineales o ramificados que incluyen de uno a veinte átomos de cárbono (C1-C20), pudiendo ser dichos sustituyentes idénticos o distintos entre sí, o seleccionándose sólo uno de dichos sustituyentes del grupo formado por radicales de arilalquilo de fórmula (CH2)nC6H5 con n=1-16; g) hidrólisis del éster de ácido R(+)a-lipoico.Synthesis process of R (+) a-lipoic acid comprising the following steps: a) salification of racemic 6,8-halo-octanoic acid with S (-) ~ -methylbenzylamine, taking the molar ratio S (-) ~ methylbenzylamine / racemic 6,8-dihalo-octanoic acid a value between 0.45 and 0.65; b) filtration separation of the crystallized diastereoisomeric salt of S (-) - methylbenzylamine-R (+) - 6 acid, dihalo-octanoic acid; c) purification by recrystallization of the diastereoisomeric salt of S (-) - methylbenzylamine-R (+) - 6, 8-dihaoctanoic acid d) separation of the diastereoisomeric salt to obtain R (+) 6, 8-dihalo-octanoic acid by the reaction of said salt with strong mineral acids diluted in an aqueous solution, the dilution being between 2% and 10% by weight; e) esterification of R (+) 6,8-dihalo-octanoic acid to obtain the corresponding alkyl ester; f) reaction of the alkyl ester of R (+) 6,8-dihalo-octanoic acid in an organic solvent with an aqueous solution of alkali disulfide in the presence of a compound for phase transfer catalysis which has been selected from the group consisting of salts quaternary phosphonium or ammonium whose general formula is: ** (formula) ** where: A is nitrogen or phosphorus, X is selected from the group consisting of CI, Br, I, HSO4 and H2PO4, and the substituents R1, R2, R3 and R4 are selected from the group consisting of linear or branched alkyl radicals that include one to twenty carbon atoms (C1-C20), said substituents being identical or distinct from each other, or only one of said substituents being selected from the group consisting of arylalkyl radicals of formula (CH2) nC6H5 with n = 1-16; g) hydrolysis of the ester of R (+) a-lipoic acid.
Description
Síntesis de ácido R(+)\alpha-lipoico.Acid synthesis R (+) α-lipoic.
La presente invención se refiere a un proceso de síntesis de ácido R(+)\alpha-lipoico a través de la formación de sales diastereoisoméricas de ácido 6,8-dihalooctanoico racémico con isómeros ópticos de a-metilbencilamina, la separación de ácido R(+)-dihalooctanoico y su transformación en el ácido \alpha-lipoico correspondiente por catálisis de transferencia de fase.The present invention relates to a process of synthesis of R (+) α-lipoic acid through formation of diastereoisomeric acid salts 6,8-racemic dihalooctanoic acid optic isomers of a-methylbenzylamine, acid separation R (+) - dihalooctanoic acid and its transformation into acid corresponding α-lipoic by catalysis of phase transfer
El procedimiento de resolución de mezclas racémicas o de racematos, es decir, la descomposición de un racemato en los enantiómeros que lo constituyen, es un procedimiento bien conocido en la técnica anterior. El racemato se transforma en primer lugar en una mezcla de diastereoisómeros mediante una reacción con una sustancia ópticamente activa. Los diastereoisómeros así obtenidos, que se caracterizan por diversas propiedades físicas entre las que se encuentra su solubilidad, se separan generalmente por cristalización fraccionada. Los enantiómeros de la mezcla racémica inicial se obtienen de dichos diastereoisómeros separados por medio de simples reacciones químicas de separación de dichos diestereoisómeros.The mixing resolution procedure racemic or racemate, that is, the decomposition of a racemate in the enantiomers that constitute it, it is a good procedure known in the prior art. The racemate becomes first place in a mixture of diastereoisomers by a reaction with an optically active substance. The diastereoisomers as well obtained, which are characterized by various physical properties among which is its solubility, they are generally separated by fractional crystallization. The enantiomers of the mixture Initial racemic are obtained from said separate diastereoisomers by means of simple chemical reactions of separation of said diestereoisomers.
En la patente U.S. 5.281.722 se describen sales diastereoisoméricas que se han obtenido de enantiómeros puros de ácido \alpha-lipoico sometiéndolos a una reacción con isómeros ópticos de \alpha-metilbencilamina. Los procedimientos conocidos describen métodos para preparar dichas sales diastereoisoméricas y su uso como productos intermedios en la resolución de una mezcla racémica de ácido tióctico en las dos formas de enantiómeros ópticamente activos R(+) y S(-) del ácido \alpha-lipoico. El procedimiento de resolución de un ácido tióctico racémico es de bajo rendimiento en el caso particular de la separación de enantiómeros R(+)\alpha-lipoicos (véanse los ejemplos 7 y 8 de la patente U.S. 5.281.722).In U.S. Patent 5,281,722 salts are described diastereoisomers that have been obtained from pure enantiomers of α-lipoic acid undergoing a reaction with optical isomers of α-methylbenzylamine. The known procedures describe methods for preparing said diastereoisomeric salts and their use as intermediates in the resolution of a racemic mixture of thioctic acid in both R (+) and S (-) optically active enantiomer forms of the acid α-lipoic. The resolution procedure of a racemic thioctic acid is low yield in the case particular of the separation of enantiomers R (+) α-lipoic (see examples 7 and 8 of U.S. Patent 5,281,722).
De hecho, los procedimientos de purificación de sales diastereoisoméricas descritos en la técnica anterior presentan un bajo enriquecimiento enantiomérico de la sal de isómero R(+)\alpha-lipoico.In fact, the purification procedures of diastereoisomeric salts described in the prior art have a low enantiomeric enrichment of the isomer salt R (+) α-lipoic.
Esto lo confirman también las numerosas recristalizaciones a las que se someten las sales diastereoisoméricas antes de la reacción de escisión con ácidos.This is also confirmed by the numerous recrystallizations to which salts are subjected diastereoisomerics before the cleavage reaction with acids
Las pruebas realizadas por el solicitante
demuestran que la escisión de sales diastereoisoméricas purificadas
mediante la adición de ácidos inorgánicos, como, por ejemplo,
ácidos minerales como ácido hidroclórico 1 N, para obtener las dos
formas de enantiómeros ópticamente activos R(+) y S(-) del ácido
\alpha-lipioco, según el procedimiento descrito
en la patente U.S. 5.281.722, proporciona enantiómeros de ácido
\alpha-lipoico de baja calidad (presencia
de
polímeros).The tests carried out by the applicant demonstrate that the cleavage of purified diastereoisomeric salts by the addition of inorganic acids, such as, for example, mineral acids such as 1 N hydrochloric acid, to obtain the two forms of optically active enantiomers R (+) and S ( -) α-lipioco acid, according to the procedure described in US Patent 5,281,722, provides enantiomers of low-quality α-lipoic acid (presence of
polymers).
La técnica anterior describe el uso de sales diastereoisoméricas obtenidas a partir de enantiómeros de ácido \alpha-lipoico mediante una reacción con bases ópticamente activas para separar los isómeros R(+) y S(-) de ácido \alpha-lipoico. Pero según las verificaciones realizadas por el solicitante, los procedimientos descritos en la técnica anterior se caracterizan por involucrar procedimientos largos y complejos para purificar las sales diestereoisoméricas intermedias, obteniéndose un bajo rendimiento en la resolución de los racematos, siendo además la calidad de los isómeros ópticos así obtenidos insatisfactoria.The prior art describes the use of salts. diastereoisomers obtained from acid enantiomers α-lipoic by a reaction with bases optically active to separate the R (+) and S (-) acid isomers α-lipoic. But according to the verifications performed by the applicant, the procedures described in the prior art are characterized by involving procedures long and complex to purify diestereoisomeric salts intermediate, obtaining a low performance in the resolution of racemates, the quality of the optical isomers being like this Obtained unsatisfactory.
Existía por consiguiente la demanda de un procedimiento de síntesis del isómero óptico R(+) de ácido \alpha-lipoico que constituyese una alternativa a los procedimientos de la técnica anterior que incluyen el ácido tióctico racémico como producto intermedio de reacción, y, en particular, la demanda de procedimientos de síntesis que proporcionasen con alto rendimiento isómeros ópticos de ácido \alpha-lipoico de calidad y pureza elevadas.There was therefore a demand for a Synthesis procedure of the optical isomer R (+) of acid α-lipoic constituting an alternative to prior art procedures that include acid racemic thioctic as a reaction intermediate, and, in in particular, the demand for synthesis procedures that provided high performance optical acid isomers α-lipoic of high quality and purity.
Se ha encontrado ahora un nuevo procedimiento de síntesis de ácido R(+)\alpha-lipoico por medio de la resolución de ácido racémico 6,8-dihalo-octanoico con la base (S)-\alpha-metilbencilamina ópticamente activa y su reacción por catálisis de transferencia de fase con el disulfuro alcalino del enantiómero esterificado del álcali-R(+)6,8-dihalo-octonoato correspondiente, superando dicho procedimiento las desventajas características de los procedimientos de la técnica anterior, como la complejidad, el bajo rendimiento y la baja calidad de los isómeros ópticos obtenidos.A new procedure has now been found synthesis of R (+) α-lipoic acid by means of racemic acid resolution 6,8-dihalo-octanoic with base (S) -? -Methylbenzylamine optically active and its reaction by transfer catalysis of phase with the alkaline disulfide of the esterified enantiomer of the alkali-R (+) 6,8-dihalo-octonoate corresponding, overcoming said procedure the disadvantages characteristics of prior art procedures, such as the complexity, the low performance and the low quality of the optical isomers obtained.
El solicitante encontró bastante inesperada y sorprendentemente un nuevo procedimiento de síntesis de ácido R(+)\alpha-lipoico por medio de la salificación de ácido 6,8-dihalo-octanoico con la base ópticamente activa de S(-)\alpha-metilbencilalina para obtener la sal diastereoisométrica de S(-)\alpha-metilbencilamina-ácido (+)-6,8-dihalo-octanoico, seguida de la purificación por cristalización fraccionada y de la escisión de la sal con ácidos, obteniéndose así el enantiómero (+) del ácido 6,8-dihalooctanoico, que, una vez esterificado, se somete a una reacción por catálisis de transferencia de fase con soluciones acuosas de disulfuros alcalinos para obtener ácido R(+)\alpha-lipoico esterificado.The applicant found quite unexpected and surprisingly a new acid synthesis procedure R (+) α-lipoic by salification of 6,8-dihalo-octanoic acid with the optically active base of S (-) α-methylbenzylalin to obtain the salt diastereoisometric of S (-) α-methylbenzylamine acid (+) - 6,8-dihalo-octanoic, followed by fractional crystallization purification and excision of the salt with acids, thus obtaining the enantiomer (+) of 6,8-dihalooctanoic acid, which, once esterified, undergoes a catalysis reaction of phase transfer with aqueous disulfide solutions alkalines to obtain R (+) α-lipoic acid esterified
Un objetivo de la presente invención consiste por tanto en un procedimiento de síntesis de ácido R(+)\alpha-lipoicio que comprende las siguientes etapas:An objective of the present invention is to both in an acid synthesis procedure R (+) α-lipoicium comprising the following stages:
a) salificación de ácido 6,8-halo-octanoico racémico con S(-)\alpha-metilbencilamina, tomando la relación molar S(-)\alpha-metilbencilamina/ácido 6,8-dihalo-octanoico racémico un valor entre 0,45 y 0,65;a) acid salification Racemic 6,8-halo-octanoic with S (-) α-methylbenzylamine, taking the ratio molar S (-) α-methylbenzylamine / acid Racemic 6,8-dihalo-octanoic one value between 0.45 and 0.65;
b) separación por filtración de la sal diastereoisomérica cristalizada de S(-)\alpha-metilbencilamina-ácido R(+)6,8-dihalo-octanoico;b) salt separation by filtration crystallized diastereoisomer of S (-) α-methylbenzylamine acid R (+) 6,8-dihalo-octanoic;
c) purificación por recristalización de la sal diastereoisomérica de S(-)\alpha-metilbencilamina-ácido R(+)-6,8-dihalo-octanoico;c) salt recrystallization purification diastereoisomeric of S (-) α-methylbenzylamine acid R (+) - 6,8-dihalo-octanoic;
d) separación de la sal diastereoisomérica para obtener ácido R(+)6,8-dihalo-octanoico mediante la reacción de dicha sal con ácidos minerales fuertes diluidos en una solución acuosa, siendo la dilución de entre 2% y 10% en peso;d) separation of the diastereoisomeric salt to get acid R (+) 6,8-dihalo-octanoic by reaction of said salt with strong mineral acids diluted in a aqueous solution, the dilution being between 2% and 10% by weight;
e) esterificación del ácido R(+)6,8-dihalo-octanoico para obtener el éster alquílico correspondiente;e) acid esterification R (+) 6,8-dihalo-octanoic for obtain the corresponding alkyl ester;
f) reacción del éster alquílico de ácido R(+)6,8-dihalo-octanoico en un solvente orgánico con una solución acuosa de disulfuro alcalino en presencia de un compuesto para la catálisis de transferencia de fase que se ha seleccionado del grupo formado por sales cuaternarias de fosfonio o amonio cuya fórmula general es:f) reaction of the acid alkyl ester R (+) 6,8-dihalo-octanoic in a organic solvent with an aqueous solution of alkaline disulfide in presence of a compound for transfer catalysis of phase that has been selected from the group formed by salts quaternary phosphonium or ammonium whose general formula is:
donde:where:
A es nitrógeno o fósforo,A is nitrogen or phosphorus,
X se selecciona del grupo formado por CI, Br, I,X is selected from the group consisting of CI, Br, I,
HSO_{4} y H_{2}PO_{4}, y los sustituyentes R_{1}, R_{2}, R_{3} y R_{4} se seleccionan del grupo formado por radicales de alquilo lineales o ramificados que incluyen de uno a veinte átomos de carbono (C_{1}-C_{20}), pudiendo ser dichos sustituyentes idénticos o distintos entre sí, o seleccionándose sólo uno de dichos sustituyentes del grupo formado por radicales de arilalquilo de fórmula (CH_{2})_{n}C_{6}H_{5} con n=1-16;HSO 4 and H 2 PO 4, and the substituents R 1, R 2, R 3 and R 4 are selected from the group formed by linear or branched alkyl radicals that include one to twenty carbon atoms (C_ {1} -C_ {20}), being able to be said identical or different substituents, or by selecting only one of said substituents of the group consisting of radicals of arylalkyl of formula (CH 2) n C 6 H 5 with n = 1-16;
g) hidrólisis del éster de ácido R(+)\alpha-lipoico.g) acid ester hydrolysis R (+) α-lipoic.
Los sustituyentes halogenados del ácido 6,8-dihalo-octanoico racémico, que pueden ser idénticos o distintos entre sí, se seleccionan del grupo formado por CI, Br e I.Halogenated Acid Substituents Racemic 6,8-dihalo-octanoic, which they can be identical or different from each other, they are selected from the group formed by CI, Br and I.
Dicho ácido 6,8-dihalo-octanoico racémico consiste preferentemente en ácido 6,8-diclorooctanoico, que es un producto que puede adquirirse fácilmente en el mercado y que se produce según la descripción incluida en J.A.C.S., volumen 79, 1957, páginas 6483-6487.Said acid Racemic 6,8-dihalo-octanoic preferably consists of acid 6,8-dichlorooctanoic acid, which is a product that can easily acquired in the market and produced according to the description included in J.A.C.S., volume 79, 1957, pages 6483-6487.
Según el procedimiento de síntesis descrito en la presente invención, la relación molar S(-)\alpha-metilbencilamina/ácido 6,8-dihalo-octanóico racémico en la etapa de salificación a) toma preferentemente un valor entre 0,48 y 0,60 y con más preferencia uno entre 0,50 y 0,58. La etapa de salificación a) se realiza a presión atmosférica y en un solvente orgánico, que consiste preferentemente en etilacetato, y a una temperatura entre 20 y 40ºC, siendo preferentemente la temperatura de entre 25 y 30ºC. La concentración de ácido 6,8-dihalo-octanóico racémico en la etapa de salificación a) es de 10 a 40% p/v, preferentemente de 15 a 35% p/v, y con más preferencia de 20 a 30% p/v de solvente.According to the synthesis procedure described in the present invention, the molar ratio S (-) α-methylbenzylamine / acid Racemic 6,8-dihalo-octanoic in the salification stage a) preferably takes a value between 0.48 and 0.60 and more preferably one between 0.50 and 0.58. The stage of salification a) is carried out at atmospheric pressure and in a solvent organic, which preferably consists of ethyl acetate, and at a temperature between 20 and 40 ° C, preferably the temperature between 25 and 30 ° C. Acid concentration Racemic 6,8-dihalo-octanoic in the salification stage a) is 10 to 40% w / v, preferably 15 at 35% w / v, and more preferably 20 to 30% w / v solvent.
La etapa b), es decir, la etapa de separación por filtración de la sal diasteriomérica se realiza a una temperatura entre 0 y 10ºC y preferentemente a 2ºC.Stage b), that is, the separation stage by filtration of the diasteriomeric salt is carried out at a temperature between 0 and 10 ° C and preferably at 2 ° C.
En la etapa c), es decir, en la etapa de purificación por recristalización de la sal diastereoisomérica de S(-)\alpha-metilbencilamina-ácido R(+)6,8-dihalo-octanoico, los solventes utilizados consisten en ésteres alquílicos de ácidos carboxílicos alifáticos o aromáticos, en los que el alquilo es C_{1}-C_{3}, y preferentemente en ésteres alquílicos de ácidos carboxílicos alifáticos con 2 a 4 átomos de carbono, realizándose dicha etapa a una temperatura entre 40 y 65ºC, aunque preferentemente entre 45 y 60ºC y con más preferencia entre 50 y 55ºC.In stage c), that is, in the stage of purification by recrystallization of the diastereoisomeric salt of S (-) α-methylbenzylamine acid R (+) 6,8-dihalo-octanoic, the Solvents used consist of alkyl esters of acids aliphatic or aromatic carboxylic acids, in which the alkyl is C 1 -C 3, and preferably in esters alkyl of aliphatic carboxylic acids with 2 to 4 atoms of carbon, said stage being carried out at a temperature between 40 and 65 ° C, although preferably between 45 and 60 ° C and more preferably between 50 and 55 ° C.
En la etapa d), es decir, en la etapa de separación de la sal diastereoisomérica, el ácido mineral acuoso consiste preferentemente en ácido sulfúrico diluido, siendo la dilución de entre 4 y 8% en peso y con más preferencia del 5% en peso.In stage d), that is, in the stage of separation of diastereoisomeric salt, aqueous mineral acid preferably consists of dilute sulfuric acid, the dilution of between 4 and 8% by weight and more preferably 5% in weight.
La etapa e), es decir, la esterificación de ácido R(+)6,8-dihalo-octanoico, comprende una reacción de esterificación según procedimientos bien conocidos en el campo de la esterificación de ácidos carboxílicos alifáticos con alcoholes alifáticos o aromáticos.Stage e), that is, acid esterification R (+) 6,8-dihalo-octanoic, comprises an esterification reaction according to well known procedures in the field of esterification of aliphatic carboxylic acids with aliphatic or aromatic alcohols.
Según la presente invención, los ésteres alquílicos de ácido R(+)6,8-dihalo-octanoico consisten en ésteres C_{1}-C_{6} lineales o ramificados, preferentemente en ésteres C_{1}-C_{3} lineales o ramificados, y con más preferencia en éster metílico o éster etílico.According to the present invention, esters acid alkyl R (+) 6,8-dihalo-octanoic consist in linear or branched C 1 -C 6 esters, preferably in linear C 1 -C 3 esters or branched, and more preferably in methyl ester or ester ethyl.
Según la presente invención, la cantidad de ésteres alquílicos de ácido R(+)6,8-dihalo-octanoico en la reacción de la etapa f) es de entre 5 y 60% en peso, preferentemente de entre 10 y 40% en peso, y con más preferencia de entre 15 y 30% en peso con respecto al solvente orgánico.According to the present invention, the amount of alkyl acid esters R (+) 6,8-dihalo-octanoic in the reaction of step f) is between 5 and 60% by weight, preferably between 10 and 40% by weight, and more preferably between 15 and 30% by weight with respect to the organic solvent.
El solvente orgánico utilizado en la reacción de la etapa f) consiste en un solvente que no puede mezclarse con agua y que se selecciona del grupo formado por hidrocarbonos C_{5}-C_{10} alifáticos, lineales o ramificados, o hidrocarbonos C_{5}-C_{10} aromáticos que comprenden también grupos sustituyentes seleccionados del grupo formado por grupos nitro, nitrito o halógeno, ésteres de ácidos carboxílicos alifáticos o aromáticos; ésteres lineales o cíclicos; quetonas C_{4}-C_{10} lineales o cíclicas; disulfuros de carbono; tetracloruros de carbono. El solvente consiste preferentemente en benceno o tolueno.The organic solvent used in the reaction of step f) consists of a solvent that cannot be mixed with water and that is selected from the group consisting of hydrocarbons C5 {C} -C10 {aliphatic, linear or branched, or C 5 -C 10 hydrocarbons aromatics also comprising substituent groups selected from the group consisting of nitro, nitrite or halogen, esters of aliphatic or aromatic carboxylic acids; linear or cyclic esters; Ketones C4 {C} {C10} linear or cyclic; disulfides of carbon; carbon tetrachlorides The solvent consists preferably in benzene or toluene.
El procedimiento de síntesis de ácido R(+)\alpha-lipoico según la presente invención comprende la transferencia de fase del ión de disulfuro de la solución acuosa, que contiene el disulfuro alcalino correspondiente, a la fase orgánica, que no puede mezclarse con agua y contiene el éster alquílico de ácido R(+)6,8-dihalo-octanoico. La solución acuosa de disulfuro alcalino puede prepararse sometiéndo azufre (S) a una reacción en agua con el sulfuro alcalino correspondiente.The acid synthesis procedure R (+) α-lipoic according to the present invention comprises the phase transfer of the disulfide ion of the aqueous solution, which contains the alkali disulfide corresponding to the organic phase, which cannot be mixed with water and contains the alkyl acidic ester R (+) 6,8-dihalo-octanoic. The aqueous solution of alkali disulfide can be prepared by subjecting sulfur (S) to a reaction in water with alkali sulphide correspondent.
Los disulfuros alcalinos preferidos son el disulfuro de sodio (Na_{2}S_{2}) y el disulfuro de potasio (K_{2}S_{2}) o una mezcla de ambos, siendo el más preferido el disulfuro de sodio.Preferred alkali disulfides are the sodium disulfide (Na2S2) and potassium disulfide (K 2 S 2) or a mixture of both, with the most preferred being sodium disulfide
En la reacción de la etapa f) del procedimiento de síntesis de ácido R(+)\alpha-lipoico según la presente invención, la relación molar disulfuro alcalino/éster alquílico de ácido R(+)6,8-dihalo-octanoico toma un valor entre 0,8 y 1,2, preferentemente entre 0,9 y 1,1, y con más preferencia entre 0,95 y 1,0.In the reaction of step f) of the procedure of synthesis of R (+) α-lipoic acid according to the present invention, the alkali disulfide / ester molar ratio acid alkyl R (+) 6,8-dihalo-octanoic takes a value between 0.8 and 1.2, preferably between 0.9 and 1.1, and with more Preference between 0.95 and 1.0.
Los compuestos preferidos para la catálisis de transferencia de fase, que se utilizan en la síntesis de ácido R(+)\alpha-lipoico objeto de la presente invención, se seleccionan del grupo formado por bromuro de tetrabutilamonio, bromuro de tetrabutilfosfonio, cloruro de metiltrioctilamonio (ALIQUAT^{(R)} 336), cloruro de metil-(C_{8}-C_{10})-trialquilamonio (ADOGEN^{(R)} 464) e hidrogenosulfato de tetrabutilamonio; y más preferentemente son bromuro de tetrabutilamonio e hidrogenosulfato de tetrabutilamonio.Preferred compounds for catalysis of phase transfer, which are used in acid synthesis R (+) α-lipoic object of the present invention, are selected from the group consisting of bromide of tetrabutylammonium, tetrabutylphosphonium bromide, chloride methyltrioctylammonium (ALIQUAT (R) 336), chloride methyl- (C 8 -C 10) - trialkylammonium (ADOGEN (R) 464) and tetrabutylammonium hydrogen sulfate; and more preferably they are tetrabutylammonium bromide and hydrogen sulfate of tetrabutylammonium.
Según el procedimiento de síntesis descrito en la presente invención, el compuesto para la catálisis de transferencia de fase, que participa en la reacción de la etapa f) y consiste en una sal cuaternaria, se encuentra en una cantidad entre 0,5 y 10% en moles, preferentemente entre 1 y 5% en moles, y con más preferencia entre 2 y 4% en moles con respecto al éster alquílico de ácido 6,8-dihalo-octanoico.According to the synthesis procedure described in the present invention, the compound for transfer catalysis phase, which participates in the reaction of stage f) and consists of a quaternary salt, is in an amount between 0.5 and 10% in moles, preferably between 1 and 5% in moles, and with more preference between 2 and 4 mol% with respect to the alkyl ester of 6,8-dihalo-octanoic acid.
La temperatura de la reacción de la etapa f) se encuentra entre 20 y 130ºC, preferentemente entre 60 y 100ºC, y con más preferencia entre 80 y 90ºC.The reaction temperature of step f) is it is between 20 and 130ºC, preferably between 60 and 100ºC, and with more preference between 80 and 90 ° C.
La etapa g), es decir, la hidrólisis del éster de ácido R(+)\alpha-lipoico, consiste en una hidrólisis con hidróxidos alcalinos/de tierras alcalinas en presencia de solventes orgánicos, tales como alcoholes y polioles, ésteres y hidroxiésteres, quetonas y hidroxiquetonas, que pueden mezclarse con agua en una relación de volúmenes de 50:50 a 95:5 y a una temperatura entre 0 y 100ºC. La concentración del éster con respecto al solvente orgánico es de entre 5 y 50% p/v y la relación molar éster/hidróxido toma un valor entre 0,5 y 1. Se puede recuperar ácido R(+)\alpha-lipoico libre mediante un tratamiento con ácidos minerales acuosos, siendo la dilución de entre 1 y 20% en peso, o mediante un tratamiento con ácidos orgánicos solubles en agua.Step g), that is, the hydrolysis of the ester of R (+) α-lipoic acid, consists of a hydrolysis with alkali hydroxides / alkaline earth in presence of organic solvents, such as alcohols and polyols, esters and hydroxy esters, ketones and hydroxyketones, which can mix with water in a volume ratio of 50:50 to 95: 5 and to a temperature between 0 and 100 ° C. The concentration of the ester with regarding the organic solvent is between 5 and 50% w / v and the ratio molar ester / hydroxide takes a value between 0.5 and 1. It can be recover free R (+) α-lipoic acid by a treatment with aqueous mineral acids, being the dilution of between 1 and 20% by weight, or by acid treatment Water soluble organic.
Los productos de la reacción y los productos intermedios se caracterizan mediante análisis de ^{1}H-NMR, masa y HPLC.The reaction products and products intermediates are characterized by analysis of 1 H-NMR, mass and HPLC.
A continuación se presentan algunos ejemplos a título de ilustración, entendiéndose que no limitan el alcance de la presente invención.Below are some examples to title of illustration, understanding that they do not limit the scope of the present invention
a) Se disuelven 40g (0,187 moles) de ácido 6,8-diclorooctanoico racémico en 150 ml de etilacetato a 25-30ºC. A esta solución se agregan seguidamente 12,3 g (0,101 moles) de S(-)-\alpha-metilbencilamina. Se enfría primero dicha solución a 18-20ºC, hasta que empiece a producirse la precipitación, y, a continuación, a 0-5ºC. Se filtra el sólido así obtenido y se procede a lavarlo con etilacetato (10 ml) para obtener 15,3 g de sal húmeda de S(-)\alpha-metilbencilamina-ácido (+)-6,8-diclorooctanoico.a) 40g (0.187 moles) of acid are dissolved 6,8-racemic dichlorooctanoic acid in 150 ml of ethyl acetate at 25-30 ° C. To this solution are added then 12.3 g (0.101 mol) of S (-) -? -Methylbenzylamine. I know first cool said solution to 18-20 ° C, until precipitation begins to occur, and then to 0-5ºC. The solid thus obtained is filtered and proceed to wash it with ethyl acetate (10 ml) to obtain 15.3 g of wet salt of S (-)? -methylbenzylamine-acid (+) - 6,8-dichlorooctanoic.
b) Los licores madre obtenidos con la
cristalización que se produce en la etapa a) se extraen con 100 ml
de ácido sulfúrico al 5% en peso, verificándose que el pH de la
fase acuosa toma un valor igual a 1. Se lava dos veces la fase
orgánica con 20 ml de agua y, a continuación, se procede a
concentrarla destilando el solvente a presión atmosférica hasta
alcanzar un volumen de 130-140m1. Se agregan a la
solución 9,75 g (0,08 moles) de
R(+)\alpha-metilbencilamina y se procede a
enfriarla primero a 18-20°C, hasta que empiece a
producirse la precipitación, y, a continuación, a
0-5°C. Se filtra el sólido y se procede a lavarlo
con 10 ml de etilacetato, obteniéndose así 8,2 g de sal húmeda de
R(+)\alpha-metilbencilamina-ácido
(-)-6,8-diclorooctanoico.b) The mother liquors obtained with the crystallization that occurs in stage a) are extracted with 100 ml of 5% sulfuric acid by weight, verifying that the pH of the aqueous phase takes a value equal to 1. It is washed twice the organic phase with 20 ml of water and then proceed to concentrate by distilling the solvent at atmospheric pressure until reaching a volume of 130-140m1. 9.75 g (0.08 mol) of R (+)? -Methylbenzylamine are added to the solution and it is cooled first to 18-20 ° C, until precipitation begins to occur, and then to
0-5 ° C The solid is filtered and washed with 10 ml of ethyl acetate, thus obtaining 8.2 g of wet salt of R (+)? -Methylbenzylamine-acid (-) - 6,8-dichloroctanoic acid.
c) Los licores madre obtenidos con la cristalización que se produce en la etapa b) se extraen con 50 ml de ácido sulfúrico al 5% en peso, verificándose que el pH de la fase acuosa toma un valor \leq1. Se lava dos veces la fase orgánica con 20 ml de agua y, a continuación, se procede a concentrarla destilando el solvente a presión atmosférica hasta alcanzar un volumen de 40-45 ml. Se agregan a la solución 50 ml de etilacetato y 9,8 g (0,081 moles) de S(-)\alpha-metilbencilamina y se procede a enfriarla primero a 18-20°C, hasta que empiece a producirse la precipitación, y, a continuación, a 0-5ºC. Se filtra el sólido y se procede a lavarlo con 10 ml de etilacetato, obteniéndose así 12 g de sal húmeda de S(-)\alpha-metilbencilamina-ácido (+)-6,8-diclorooctanoico.c) The mother liquors obtained with the crystallization that occurs in stage b) is extracted with 50 ml of 5% sulfuric acid by weight, verifying that the pH of the aqueous phase takes a value ≤1. The phase is washed twice organic with 20 ml of water and then proceed to concentrate it by distilling the solvent at atmospheric pressure until reach a volume of 40-45 ml. They are added to the 50 ml solution of ethyl acetate and 9.8 g (0.081 mol) of S (-)? -Methylbenzylamine and proceed to cool first to 18-20 ° C, until it starts to precipitation occurs, and then to 0-5ºC. The solid is filtered and washed with 10 ml of ethyl acetate, thus obtaining 12 g of wet salt from S (-) α-methylbenzylamine acid (+) - 6,8-dichlorooctanoic.
d) Se juntan las sales húmedas de S(-)\alpha-metilbencilamina-ácido (+)-6,8-diclorooctanoico obtenidas en las etapas a) y c) y se cristalizan dos veces utilizando cada vez 55 ml de etilacetato. Se obtienen 16 g de producto húmedo que se seca al vacío, obteniéndose así 13,5 g de la sal de S(-)\alpha-metilbencilamina-ácido (+)-6,8-diclorooctanoico. Se suspende dicha sal en una mezcla de agua (60 ml) y tolueno (60 ml) y se procede a acidificarla con ácido sulfúrico al 5% en peso hasta alcanzar un pH \cong 1. Se separa la fase orgánica y se procede a concentrarla al vacío, obteniéndose así 9 g de ácido (+)-6,8-diclorooctanoico (rendimiento del 45%).d) The wet salts of S (-) α-methylbenzylamine acid (+) - 6,8-dichlorooctanoic obtained in stages a) and c) and crystallize twice using each time 55 ml of ethyl acetate. 16 g of wet product are obtained which dried under vacuum, thus obtaining 13.5 g of the salt of S (-) α-methylbenzylamine acid (+) - 6,8-dichlorooctanoic. I know suspend said salt in a mixture of water (60 ml) and toluene (60 ml) and proceed to acidify it with 5% sulfuric acid by weight until reach a pH 1. 1. The organic phase is separated and proceed to concentrate in vacuo, thus obtaining 9 g of acid (+) - 6,8-dichlorooctanoic (45% yield).
[\alpha]^{24}_{D} = 26,7 (c= 2, etanol)[α] 24 D = 26.7 (c = 2, ethanol)
Se disuelven 9 g (0,042 moles) de ácido (+)-6,8-diclorooctanoico en 120 ml de metanol que contiene 0,45 ml de ácido clorhídrico al 37% en peso. Se calienta la solución a reflujo durante dos horas, se evapora el solvente a presión reducida, se agregan 17 ml de tolueno y se procede a lavar dos veces con 10 ml de agua la solución así obtenida. La fase de tolueno se concentra seguidamente al vacío, obteniéndose así 9,4 g de metil (+)-6,8-diclorooctanoato (rendimiento del 98,6%).9 g (0.042 mol) of acid are dissolved (+) - 6,8-dichlorooctanoic acid in 120 ml of methanol containing 0.45 ml of 37% hydrochloric acid in weight. The solution is heated at reflux for two hours, evaporate the solvent under reduced pressure, 17 ml of toluene are added and the solution is washed twice with 10 ml of water obtained. The toluene phase is then concentrated in vacuo, thus obtaining 9.4 g of methyl (+) - 6,8-dichlorooctanoate (98.6% yield).
[\alpha]^{20}_{D} = 26,5 (c = 1, tolueno)[α] 20 D = 26.5 (c = 1, toluene)
Se calienta a 85ºC y durante 30 minutos una mezcla de 5,65 g (0,043 moles) de sulfuro de sodio al 60% en peso, 1,18 g (0,037 moles) de sulfuro y 20 ml de agua. Tras filtrar la mezcla para extraer la parte no soluble, se agrega durante tres horas la solución obtenida a una solución formada por 9,4 g (0,041 moles) de metil (+)-6,8-diclorooctanoato, 0,37 g (0,0011 moles) de bromuro de tetrabutilamonio y 18,5 ml de tolueno, manteniéndose la solución a 82ºC. Se calienta la mezcla a reflujo (90ºC) durante 1 hora y se procede seguidamente a enfriarla a 30ºC. Se separa la fase orgánica y se procede a lavarla con 5 ml de agua. A continuación, se concentra todo al vacío, obteniéndose así 8,6 g de éster metílico del ácido R(+)\alpha-lipoico (rendimiento del 94,4%).It is heated at 85 ° C and for 30 minutes a mixture of 5.65 g (0.043 mol) of 60% by weight sodium sulfide, 1.18 g (0.037 mol) of sulfide and 20 ml of water. After filtering the mixture to extract the non-soluble part, is added for three hours the solution obtained to a solution formed by 9.4 g (0.041 moles) of methyl (+) - 6,8-dichlorooctanoate, 0.37 g (0.0011 mol) of tetrabutylammonium bromide and 18.5 ml of toluene, keeping the solution at 82 ° C. The mixture is heated to reflux (90 ° C) for 1 hour and then cooled to 30 ° C. The organic phase is separated and washed with 5 ml of water. Then, everything is concentrated under vacuum, thus obtaining 8.6 g of R (+) α-lipoic acid methyl ester (94.4% yield).
El producto final se caracteriza mediante análisis de ^{1}H-NMR y masa:The final product is characterized by 1 H-NMR and mass analysis:
- --
- ^{1}H-NMR - \delta (300 MHz, CDCI_{3}): 1,4 (2H,m); 1,67 (4H,m); 1,83 (1 H,td); 2,24 (2H,t); 2,4 (1 H,td); 3,1 (2H,m); 3,5 (1 H,m); 3,66 (3H,s).1 H-NMR - δ (300 MHz, CDCI3): 1.4 (2H, m); 1.67 (4H, m); 1.83 (1 H, td); 2.24 (2H, t); 2.4 (1 H, td); 3.1 (2H, m); 3.5 (1 H, m); 3.66 (3H, s).
- --
- Masa (El): 220 (M^{+}); 189 (-CH_{3}O)Mass (El): 220 (M +); 189 (-CH 3 O)
[\alpha]^{20}_{D} = 88 (c = 1,8 tolueno)[α] 20 D = 88 (c = 1.8 toluene)
Se agregan 8,6 g (0,039 moles) de éster metílico del ácido R(+)\alpha-lipoico a una solución que consiste en 2,36 g (0,042 moles) de hidróxido de potasio al 95% en peso, 19 ml de metanol y 3,8 ml de agua. Se calienta la mezcla obtenida durante dos horas a 50ºC, se procede a enfriarla a 30ºC y se le agregan seguidamente 40 ml de tolueno. Se acidifica todo con ácido fosfórico al 10% en peso, manteniendo la temperatura por debajo de los 30ºC. Se separa la fase orgánica y se procede a lavarla tres veces utilizando cada vez 10 ml de una solución acuosa de cloruro de sodio al 10% en peso. Se deshidrata la solución sobre sulfato de sodio y se procede a concentrarla hasta la sequedad evaporando el solvente al vacío. Se agregan 3,3 ml de etilacetato y 41 ml de ciclohexano, se calienta la solución a 40ºC, se procede a tratarla con carbón decolorante y se enfría lentamente la solución clara así obtenida hasta alcanzar los 0ºC. Se filtra el material sólido y se procede a lavarlo con 5 ml de ciclohexano, obteniéndose así 3,6 g de ácido R(+)\alpha-lipoico (rendimiento del 45%).8.6 g (0.039 mol) of methyl ester are added of the R (+) α-lipoic acid to a solution that consists of 2.36 g (0.042 moles) of 95% potassium hydroxide in weight, 19 ml of methanol and 3.8 ml of water. The mixture is heated obtained for two hours at 50 ° C, it is cooled to 30 ° C and 40 ml of toluene are then added. Everything is acidified with 10% phosphoric acid by weight, maintaining the temperature by below 30 ° C. The organic phase is separated and the wash it three times using 10 ml of an aqueous solution each time of 10% by weight sodium chloride. The solution is dehydrated on sodium sulfate and proceed to concentrate until dry evaporating the solvent in vacuo. 3.3 ml of ethyl acetate are added and 41 ml of cyclohexane, the solution is heated to 40 ° C, proceed to treat it with decolorizing carbon and slowly cool the solution clear thus obtained until reaching 0 ° C. The material is filtered solid and proceed to wash it with 5 ml of cyclohexane, obtaining thus 3.6 g of R (+) α-lipoic acid (45% yield).
[\alpha]^{20}_{D} = 119,1 (c = 1, etanol)[α] 20 D = 119.1 (c = 1, ethanol)
e.e>99% (HPLC).e.e> 99% (HPLC).
Claims (31)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2000MI002188A IT1319196B1 (en) | 2000-10-10 | 2000-10-10 | SUMMARY OF R (+) ALPHA-LIPOIC ACID. |
ITMI20002188 | 2000-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2219577T3 true ES2219577T3 (en) | 2004-12-01 |
Family
ID=11445937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES01986686T Expired - Lifetime ES2219577T3 (en) | 2000-10-10 | 2001-10-08 | SYNTHESIS OF ACID R (+) ALPHA-LIPOIC. |
Country Status (11)
Country | Link |
---|---|
US (1) | US6864374B2 (en) |
EP (1) | EP1335911B1 (en) |
JP (1) | JP4257574B2 (en) |
KR (1) | KR100822532B1 (en) |
AT (1) | ATE266020T1 (en) |
AU (1) | AU2002220596A1 (en) |
CZ (1) | CZ301710B6 (en) |
DE (1) | DE60103179T2 (en) |
ES (1) | ES2219577T3 (en) |
IT (1) | IT1319196B1 (en) |
WO (1) | WO2002030919A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10201464B4 (en) * | 2002-01-16 | 2005-06-16 | Viatris Gmbh & Co. Kg | Process for the preparation of pure thioctic acid |
ITMI20030831A1 (en) | 2003-04-22 | 2004-10-23 | Laboratorio Chimico Int Spa | BASIC SALT OF TIOTIC ACID WITH L-CARNITINE. |
CN100387593C (en) * | 2006-01-26 | 2008-05-14 | 南京师范大学 | Method for separating dithio-octanoic acid and buck solution using continuous reflux liquid-liquid extraction method |
ITMI20061024A1 (en) | 2006-05-25 | 2007-11-26 | Eurand Pharmaceuticals Ltd | PELLETS BASED ON LIPOIC ACID |
CA2741700A1 (en) * | 2008-10-24 | 2010-04-29 | Biolink Life Sciences, Inc. | Stable, water-insoluble r-(+)-.alpha.-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities |
RU2011124739A (en) * | 2008-12-01 | 2013-01-10 | Инваск Терапьютикс, Инк. | COMPOSITIONS CONTAINING ALENOSTERONE RENIN-ANGIOTENSIN SYSTEM INHIBITORS AND LIPOIC ACID COMPOUNDS, AND THEIR APPLICATION FOR TREATMENT OF DISEASES CONNECTED WITH RENIN-ANGIOTENOSIS SYSTEM |
CN101880224B (en) * | 2009-05-08 | 2013-02-20 | 上海医药工业研究院 | Method for splitting 6,8-dichlorocaprylate |
US8080674B2 (en) * | 2009-06-12 | 2011-12-20 | Ampac Fine Chemicals Llc. | Preparation of polymer-free R-(+)-α-lipoic acid magnesium salt |
DE102012109704A1 (en) * | 2012-10-11 | 2014-04-17 | Epcos Ag | Ceramic component with protective layer and method for its production |
CN109942426B (en) * | 2019-04-02 | 2022-03-22 | 福建科宏生物工程股份有限公司 | Treatment method for recycling S- (-) -lipoic acid |
CN116496245B (en) * | 2023-03-01 | 2024-10-01 | 杭州新曦科技有限公司 | Process for preparing R-alpha-lipoic acid and related intermediates thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3629116A1 (en) | 1986-08-27 | 1988-03-10 | Asta Pharma Ag | METHOD FOR PRODUCING ENANTIOMERALLY PURE R - (+) - (ALPHA) -LIPONIC ACID AND S - (-) - (ALPHA) -LIPONIC ACID (THIOCTS ACID) AND NON-RELATED MESYL DERIVATIVES AS INTERMEDIATE PRODUCTS |
DE3814163A1 (en) * | 1988-04-27 | 1989-11-09 | Rhein Chemie Rheinau Gmbh | METHOD FOR PRODUCING DISULFIDES |
DE4137773A1 (en) | 1991-11-16 | 1993-05-19 | Degussa | PRODUCTION AND USE OF SALTS OF THE PURE ENANTIOMERS OF (ALPHA) LIPONIC ACID |
DE4342619A1 (en) * | 1993-12-14 | 1995-06-22 | Bayer Ag | Improved process for the preparation of 2,2'-dinitrodiphenyl disulfide |
DE19510130C1 (en) * | 1995-03-21 | 1996-11-21 | Asta Medica Ag | Process for the preparation of free-flowing R, S-thioctic acid, R, S-thioctic acid and their use |
GB9510858D0 (en) * | 1995-05-30 | 1995-07-26 | Chiroscience Ltd | Process for preparing lipoic acid |
DE19533881A1 (en) * | 1995-09-13 | 1997-03-20 | Dresden Arzneimittel | Production and use of the pure enantiomers of 8-chloro-6-sulfonyloxy-octanoic acids and their alkyl esters and of the pure enantiomers of 6,8-dichloro-octanoic acid and their alkyl esters |
IL123887A0 (en) * | 1997-04-02 | 1998-10-30 | Sankyo Co | Dithiolan derivatives their use and pharmaceutical compositions containing the same |
DE69920497T2 (en) * | 1998-10-26 | 2006-02-09 | The Research Foundation Of State University Of New York | LIPONSAÜREDERIVATE AND ITS USE IN THE TREATMENT OF DISEASES |
AR042572A1 (en) * | 1999-04-02 | 2005-06-29 | Sod Conseils Rech Applic | DERIVATIVES OF LIPOIC ACID, PROCEDURE FOR THE PREPARATION, MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF SUCH DERIVATIVES FOR THE PREPARATION OF THE REFERRED MEDICATIONS |
DE19938621A1 (en) * | 1999-08-14 | 2001-02-22 | Sueddeutsche Kalkstickstoff | Process for the production of solvent-free alpha-lipoic acid |
IT1319195B1 (en) * | 2000-10-10 | 2003-09-26 | Laboratorio Chimico Int Spa | PROCESS FOR THE PRODUCTION OF R (+) ALPHA-LIPOIC ACID. |
-
2000
- 2000-10-10 IT IT2000MI002188A patent/IT1319196B1/en active
-
2001
- 2001-10-08 JP JP2002534305A patent/JP4257574B2/en not_active Expired - Fee Related
- 2001-10-08 WO PCT/EP2001/011576 patent/WO2002030919A1/en active IP Right Grant
- 2001-10-08 DE DE60103179T patent/DE60103179T2/en not_active Expired - Lifetime
- 2001-10-08 CZ CZ20031007A patent/CZ301710B6/en not_active IP Right Cessation
- 2001-10-08 EP EP01986686A patent/EP1335911B1/en not_active Expired - Lifetime
- 2001-10-08 KR KR1020037004734A patent/KR100822532B1/en not_active IP Right Cessation
- 2001-10-08 AT AT01986686T patent/ATE266020T1/en not_active IP Right Cessation
- 2001-10-08 US US10/398,890 patent/US6864374B2/en not_active Expired - Lifetime
- 2001-10-08 AU AU2002220596A patent/AU2002220596A1/en not_active Abandoned
- 2001-10-08 ES ES01986686T patent/ES2219577T3/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP4257574B2 (en) | 2009-04-22 |
US6864374B2 (en) | 2005-03-08 |
AU2002220596A1 (en) | 2002-04-22 |
ITMI20002188A1 (en) | 2002-04-10 |
ATE266020T1 (en) | 2004-05-15 |
CZ301710B6 (en) | 2010-06-02 |
JP2004511477A (en) | 2004-04-15 |
DE60103179T2 (en) | 2005-05-04 |
KR100822532B1 (en) | 2008-04-16 |
KR20030070001A (en) | 2003-08-27 |
EP1335911A1 (en) | 2003-08-20 |
EP1335911B1 (en) | 2004-05-06 |
ITMI20002188A0 (en) | 2000-10-10 |
US20040002610A1 (en) | 2004-01-01 |
IT1319196B1 (en) | 2003-09-26 |
DE60103179D1 (en) | 2004-06-09 |
WO2002030919A1 (en) | 2002-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2219577T3 (en) | SYNTHESIS OF ACID R (+) ALPHA-LIPOIC. | |
PL185034B1 (en) | Method of obtaining (s)-3-(aminomethyl)-5-methylohexanic acid | |
EP0543088A1 (en) | Preparation and use of salts of the pure enantiomers of alpha-lipoic acid | |
EP0623104B1 (en) | Profen resolution | |
ES2254522T3 (en) | ALFA-LIPOIC ACID PRODUCTION PROCEDURE. | |
ES2222399T3 (en) | METHOD FOR THE PRODUCTION OF RACEMIC THIOCTIC ACID. | |
ES2285116T3 (en) | CLOPIDOGREL PREPARATION PROCEDURE. | |
ES2449494T3 (en) | Procedure for the production of 9-cis-retinoic acid | |
PL204820B1 (en) | Resolution process for (r)-(-)-2-hydroxy-2-(2-chlorophenyl)acetic acid | |
CA2725997A1 (en) | Process for the preparation of clopidogrel hydrogen sulfate crystalline form i | |
US5591859A (en) | Process for the production of 2-cyanoiminothiazolidine | |
ES2227069T3 (en) | PRODUCTION METHOD OF AN AROMATIC ACETILTIOCARBOXILIC ACID DERIVATIVE. | |
RU2128166C1 (en) | Method of preparing amino acid n-monoalkyl derivatives and method of preparing n-alkyl-aminoiminomethanesulfonic acid | |
EP1853545B1 (en) | Process for obtaining enantiomers of chrysanthemic acid | |
JP4109446B2 (en) | Process for producing pure trans-2-[(α-methylbenzyl) amino] cyclopentanol as a diastereoisomer | |
JP2003095991A (en) | Method for producing optically active 3,3,3-trifluoro-2- hydroxy-2-methylpropionic acid | |
RU1795969C (en) | Method of benzoylurea derivatives synthesis | |
KR830000025B1 (en) | Chemical Degradation of Racemic Mandelic Acid | |
CS272527B1 (en) | Method of optically active cis-cycloeutanone preparation | |
JPH023627A (en) | Production of optically active 1-methyl-3-phenylpropylamine | |
JPS62126162A (en) | 2,3,5,6-tetrafluoro-4-mercaptobenzonitrile and production thereof | |
JPH04108766A (en) | Production of optically active 1-methyl-3-phenylpropylamine | |
JPH03258762A (en) | Aroylthiooxime and preparation thereof |